Fingerprint
Dive into the research topics of 'Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically